For research use only. Not for use in humans.

Befovacimab (Anti-TFPI)

Synonyms: BAY 1093884 Cat.No.A2779 Purity:99%

Befovacimab (anti-TFPI) is a fully human monoclonal IgG2 antibody able to bind to tissue factor pathway inhibitors (TFPI) with the potential to be used in haemophilia A/B research. MW: 143.24 kD.

Befovacimab (Anti-TFPI)

Quality Control

Batch: Purity: 99% Protein concentration: 9.488mg/ml Endotoxin Level: ＜1EU/mg

99

Specificity

Expand to Check More

1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description	Befovacimab (anti-TFPI) is a fully human monoclonal IgG2 antibody able to bind to tissue factor pathway inhibitors (TFPI) with the potential to be used in haemophilia A/B research. MW: 143.24 kD.
References	https://pubmed.ncbi.nlm.nih.gov/35667016/

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

Product Details

CAS No.	2156634-62-5
Molecular Weight	143.24
Isotype	Human IgG2SA
Source	CHO
Purification	AKTA
Sterility	0.2 μM filtered
Formulation	100 mM Pro-Ac, 20mM Arg, pH5.0
Storage (From the date of receipt)	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

^*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.